- Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogenMarianne Canonico
Hormones and Cardiovascular disease, CESP Centre for researchin Epidemiology and Population Health, U1018, INSERM, Villejuif, France
Menopause 17:1122-7. 2010..However, the differential effects of progesterone and norpregnanes on hemostasis have not yet been investigated...
- Endogenous oestradiol as a positive correlate of plasma fibrinogen among older postmenopausal women: a population-based study (the Three-City cohort study)Marianne Canonico
Hormones and Cardiovascular disease, Univ Paris Sud, Villejuif, France
Clin Endocrinol (Oxf) 77:905-10. 2012..However, whether endogenous sex steroid hormones influence the plasma fibrinogen concentrations among postmenopausal women remains unclear...
- Progestogens and venous thromboembolism among postmenopausal women using hormone therapyMarianne Canonico
Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, Villejuif, France
Maturitas 70:354-60. 2011..In conclusion, progestogens may have differential effects on VTE risk according to the molecules and therefore represent an important potential determinant of the thrombotic risk among postmenopausal women using estrogens...
- Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal womenMarianne Canonico
Institut National de la Santé et de la Recherche Médicale INSERM Unit 780 U780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, Villejuif Cedex, F 94807 France
J Clin Endocrinol Metab 93:3082-7. 2008..This effect may be modulated by the expression of cytochromes P450 3A5 (CYP3A5) and 1A2 (CYP1A2) which are involved in the hepatic metabolism of estrogens...
- Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, Cedex, France
Arterioscler Thromb Vasc Biol 30:340-5. 2010..Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established...
- Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER StudyElodie Bouaziz
Laboratoire de Genetique Moleculaire, Pharmacogénétique et Hormonologie, Hopital Bicetre, AP HP, Univ Paris Sud, 78, rue du General Leclerc, F 94275 Le Kremlin Bicêtre Cedex, France
Maturitas 64:136-8. 2009..hPR polymorphism appears not to have a significant effect on VTE risk related to HT...
- Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
Circulation 115:840-5. 2007..Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen...
- Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, Villejuif Cedex, France
BMJ 336:1227-31. 2008..To assess the risk of venous thromboembolism in women using hormone replacement therapy by study design, characteristics of the therapy and venous thromboembolism, and clinical background...
- Hormone therapy and recurrence of venous thromboembolism among postmenopausal womenValérie Olié
Hormones and Cardiovascular disease team, CEPH Centre for research in Epidemiology and Population Health, U1018, INSERM, F94807, Villejuit, France
Menopause 18:488-93. 2011..However, the impact of transdermal estrogens on VTE recurrence risk has not been investigated. The aim of our study was to assess the impact of HT by route of estrogen administration on the risk of recurrent VTE...
- Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal womenValérie Olié
INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, Universite Paris Sud, UMRS 1018, Villejuif, France
Curr Opin Hematol 17:457-63. 2010..Transdermal estrogens may be safer but early results need to be confirmed. This review provides a summary of the most recent findings regarding the VTE risk among oral versus transdermal estrogens users...
- Postmenopausal hormone therapy and venous thromboembolismValérie Olié
INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, F 94807 Villejuif, France
Thromb Res 127:S26-9. 2011..Because venous thromboembolism (VTE) is the main harmful effect of HT among young postmenopausal women, reducing VTE risk appears to be a relevant strategy to improve the benefit/risk profile of HT among postmenopausal women...
- High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort studyValérie Scarabin-Carré
Centre for research in Epidemiology and Population Health, Inserm Unit 1018, Hormones and Cardiovascular disease, Villejuif, France V S, M C, G P B, P Y S Université Paris Sud, UMR S 1018, Villejuif, France V S, M C, P D, P Y S
J Am Heart Assoc 1:e001388. 2012..Despite evidence that estrogens may be involved in atherothrombosis, the role of endogenous sex steroid hormones in ischemic arterial disease among postmenopausal women remains uncertain...
- Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trialsMarianne Canonico
From the 1Hormones and Cardiovascular Disease, Center for Research in Epidemiology and Population Health, Villejuif, France 2Université Paris Sud, UMRS 1018, Villejuif, France 3Paris Descartes University and Cochin Port Royal Hospital, Paris, France 4Department of Obstetrics and Gynecology, Miller School of Medicine, University of Miami, Miami, FL 5Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA 6University of Washington School of Nursing, Seattle, WA and 7Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA
Menopause 21:214-20. 2014....